source
- Coultreon secures $125M Series A to advance oral immune drug into Phase 2 trialsCoultreon Biopharma announced a $125 million Series A financing round to fund development of an oral drug it licensed from Galapagos. The round was led by Sofinnova Investments and included nine i…
- Coultreon Biopharma secures $125M to advance SIK inhibitor for autoimmune diseasesCoultreon Biopharma announced a $125 million financing round on April 28, 2026, backed by major biotech investors from the United States and Europe. The capital will be used to develop a new appro…